Host: Joshua E. Reuss, MD The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the last few years. This program aims

Host: Charu Aggarwal, MD, MPH Host: Joshua E. Reuss, MD The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the

Host: Charu Aggarwal, MD, MPH Host: Joshua E. Reuss, MD The role of immunotherapy (IO) in the management of advanced and metastatic NSCLC continues to evolve, with several new frontline IO-based therapy regimens receiving FDA approval in the

Host: Tessa Laubscher, MBChB, CCFP, FCFP Guest: George L. Bakris, MD, FAHA, FASN Guest: Mikhail Kosiborod, MD Managing chronic kidney disease (CKD) and type 2 diabetes (T2D) with multiple medications has become a challenge, and a multidi

Host: Piotr Ponikowski, MD, PhD, FESC, FHFA Guest: Robert J. Mentz, MD, FHFSA, FACC, FAHA While multiple clinical trials demonstrated a positive impact on patient outcomes with IV iron therapy in patients with HFrEF and iron deficiency, few

Host: Ileana L. Pia, MD, MPH, FAHA, FACC Guest: Javed Butler, MD, MBA, MPH Guest: Patrick Rossignol, MD, PhD With more effective ways to manage hyperkalemia, is it still a challenge in 2023? Chairperson Ileana Pia, MD, and faculty memb

Host: Jennifer Caudle, DO Guest: John F. Brandsema, MD Guest: Vamshi K. Rao, MD Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Becau

Host: Ioana Preston, MD Host: Oksana A. Shlobin, MD Host: Richard N. Channick, MD While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that

Host: Ioana Preston, MD While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medications,

Host: Oksana A. Shlobin, MD While there are now many effective drug treatments for PAH and PH, new molecular pathways of disease offer horizons for novel therapeutic developments that may, alone or in combination with existing, approved medicati